Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
Authors:
- Joel MorrisJMJoel Morris
- Mark W. KunkelMKMark W. Kunkel
- Stephen L. WhiteSWStephen L. White
- Donn G. WishkaDWDonn G. Wishka
- Omar D. LopezOLOmar D. Lopez
- Lori BowlesLBLori Bowles
- Penny Sellers BradyPBPenny Sellers Brady
- Patricia RamseyPRPatricia Ramsey
- Julie GramsJGJulie Grams
- Tiffany RohrerTRTiffany Rohrer
- Karen MartinKMKaren Martin
- Thomas S. DexheimerTDThomas S. Dexheimer
Open Access
- 7 August 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (11) , 1270-1279
Abstract
The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.Keywords
All Related Versions
Funding Information
- N/A
This publication has 50 references indexed in Scilit:
- The Exomes of the NCI-60 Panel: A Genomic Resource for Cancer Biology and Systems PharmacologyCancer Research, 2013
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell LinesMolecular Cancer Therapeutics, 2010
- mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug ActivitiesMolecular Cancer Therapeutics, 2010
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- A gene expression database for the molecular pharmacology of cancerNature Genetics, 2000